BACKGROUND: Approximately 60 million people in the United States live with one of four chronic conditions: heart disease, diabetes, chronic respiratory disease, and major depression. Anxiety and depression are very common comorbidities in COPD and have significant impact on patients, their families, society, and the course of the disease. METHODS: We report the proceedings of a multidisciplinary workshop on anxiety and depression in COPD that aimed to shed light on the current understanding of these comorbidities, and outline unanswered questions and areas of future research needs. RESULTS: Estimates of prevalence of anxiety and depression in COPD vary widely but are generally higher than those reported in some other advanced chronic diseases. Untreated and undetected anxiety and depressive symptoms may increase physical disability, morbidity, and health-care utilization. Several patient, physician, and system barriers contribute to the underdiagnosis of these disorders in patients with COPD. While few published studies demonstrate that these disorders associated with COPD respond well to appropriate pharmacologic and nonpharmacologic therapy, only a small proportion of COPD patients with these disorders receive effective treatment. CONCLUSION: Future research is needed to address the impact, early detection, and management of anxiety and depression in COPD.
BACKGROUND: Approximately 60 million people in the United States live with one of four chronic conditions: heart disease, diabetes, chronic respiratory disease, and major depression. Anxiety and depression are very common comorbidities in COPD and have significant impact on patients, their families, society, and the course of the disease. METHODS: We report the proceedings of a multidisciplinary workshop on anxiety and depression in COPD that aimed to shed light on the current understanding of these comorbidities, and outline unanswered questions and areas of future research needs. RESULTS: Estimates of prevalence of anxiety and depression in COPD vary widely but are generally higher than those reported in some other advanced chronic diseases. Untreated and undetected anxiety and depressive symptoms may increase physical disability, morbidity, and health-care utilization. Several patient, physician, and system barriers contribute to the underdiagnosis of these disorders in patients with COPD. While few published studies demonstrate that these disorders associated with COPD respond well to appropriate pharmacologic and nonpharmacologic therapy, only a small proportion of COPDpatients with these disorders receive effective treatment. CONCLUSION: Future research is needed to address the impact, early detection, and management of anxiety and depression in COPD.
Authors: R J White; S T Rudkin; J Ashley; V A Stevens; S Burrows; J C Pounsford; G Cratchley; N R Ambler Journal: J R Coll Physicians Lond Date: 1997 Sep-Oct
Authors: Elyse R Thakur; Shubhada Sansgiry; Nancy J Petersen; Melinda Stanley; Mark E Kunik; Aanand D Naik; Jeffrey A Cully Journal: Int J Behav Med Date: 2018-02
Authors: Muirne C S Paap; Christina Bode; Lonneke I M Lenferink; Caroline B Terwee; Job van der Palen Journal: Qual Life Res Date: 2014-11-16 Impact factor: 4.147
Authors: Mark D Eisner; Paul D Blanc; Edward H Yelin; Patricia P Katz; Gabriela Sanchez; Carlos Iribarren; Theodore A Omachi Journal: Thorax Date: 2010-03 Impact factor: 9.139
Authors: Darcy D Marciniuk; Donna Goodridge; Paul Hernandez; Graeme Rocker; Meyer Balter; Pat Bailey; Gord Ford; Jean Bourbeau; Denis E O'Donnell; Francois Maltais; Richard A Mularski; Andrew J Cave; Irvin Mayers; Vicki Kennedy; Thomas K Oliver; Candice Brown Journal: Can Respir J Date: 2011 Mar-Apr Impact factor: 2.409
Authors: Jungeun Lee; Huong Q Nguyen; Monica E Jarrett; Pamela H Mitchell; Kenneth C Pike; Vincent S Fan Journal: Heart Lung Date: 2018-02-01 Impact factor: 2.210